These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 10696734

  • 1. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
    Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE.
    Cancer J Sci Am; 2000; 6(1):21-4. PubMed ID: 10696734
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W, Weltermann A, Chott A, Gisslinger H, Valent P, Jäger U, Geissler K, Lechner K.
    Wien Klin Wochenschr; 1999 Dec 23; 111(24):1027-30. PubMed ID: 10677889
    [Abstract] [Full Text] [Related]

  • 4. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M, Rolović Z, Radosević N, Draguljac N, Jovanović V, Bogdanović A, Bosković D.
    Srp Arh Celok Lek; 2000 Dec 23; 128(7-8):262-70. PubMed ID: 11089434
    [Abstract] [Full Text] [Related]

  • 5. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O, Tomová A, Kusenda J, Gyárfás J.
    Neoplasma; 2001 Dec 23; 48(5):350-7. PubMed ID: 11845978
    [Abstract] [Full Text] [Related]

  • 6. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M, Machaczka M, Załuska A, Skotnicki AB.
    Przegl Lek; 1998 Dec 23; 55(7-8):400-6. PubMed ID: 10021885
    [Abstract] [Full Text] [Related]

  • 7. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences).
    Chrobák L, Podzimek K, Zak P, Plísková L, Voglová J.
    Acta Haematol Pol; 1995 Dec 23; 26(2 Suppl 1):56-62. PubMed ID: 7653236
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B.
    Rocz Akad Med Bialymst; 2004 Dec 23; 49():246-51. PubMed ID: 15631351
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC.
    Clin Cancer Res; 1999 Jul 23; 5(7):1665-70. PubMed ID: 10430066
    [Abstract] [Full Text] [Related]

  • 10. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
    Zák P, Chrobák L, Dĕdic K, Podzimek K.
    Vnitr Lek; 2000 Oct 23; 46(10):697-703. PubMed ID: 11344629
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ.
    Semin Oncol; 2000 Apr 23; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [Abstract] [Full Text] [Related]

  • 12. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
    Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D.
    Cancer; 2005 Dec 01; 104(11):2442-8. PubMed ID: 16245328
    [Abstract] [Full Text] [Related]

  • 13. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).
    Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ.
    N Engl J Med; 1987 Apr 02; 316(14):825-30. PubMed ID: 2434850
    [Abstract] [Full Text] [Related]

  • 14. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
    Gottschlich S, Görögh T, Lippert BM, Niemann AM, Folz BJ, Werner JA.
    Anticancer Res; 1997 Apr 02; 17(4B):2921-2. PubMed ID: 9329564
    [Abstract] [Full Text] [Related]

  • 15. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
    Wakao D, Murohashi I, Tominaga K, Yoshida K, Kishimoto K, Yagasaki F, Itoh Y, Itoh K, Sakata T, Kawai N, Kayano H, Suzuki T, Matsuda A, Hirashima K, Bessho M.
    Ann Hematol; 2002 Mar 02; 81(3):140-6. PubMed ID: 11904739
    [Abstract] [Full Text] [Related]

  • 16. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S, Ishikawa S, Yamauchi A, Saitou S.
    Hinyokika Kiyo; 2000 Oct 02; 46(10):695-9. PubMed ID: 11215193
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL, Magagnoli M, Bendandi M, Tani M, Stefoni V, Cellini C, Poggi S, Piccioli M, Pileri S, Tura S.
    Haematologica; 2000 Sep 02; 85(9):922-5. PubMed ID: 10980629
    [Abstract] [Full Text] [Related]

  • 18. Biological markers and minimal residual disease in hairy cell leukemia.
    Lauria F, Raspadori D, Benfenati D, Rondelli D, Pallotti A, Tura S.
    Leukemia; 1992 Nov 02; 6 Suppl 4():149-51. PubMed ID: 1359204
    [Abstract] [Full Text] [Related]

  • 19. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
    Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM.
    Blood; 1990 Nov 15; 76(10):1941-5. PubMed ID: 1700727
    [Abstract] [Full Text] [Related]

  • 20. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL.
    Br J Cancer; 2000 Oct 15; 83(7):847-52. PubMed ID: 10970683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.